Evidence map›Paper›PMID 39149488›Full record

ArticleResearch square2024

Comparative profiling of white matter development in the human and mouse brain reveals volumetric deficits and delayed myelination in Angelman syndrome.

Siddhi S Ozarkar, Ridthi K-R Patel, Tasmai Vulli, Audrey L Smith, Mark D Shen, Alain C Burette, Benjamin D Philpot, Martin A Styner, Heather C Hazlett

Abstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Siddhi S OzarkarNeuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Ridthi K-R PatelNeuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Tasmai VulliNeuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Audrey L SmithNeuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Mark D ShenNeuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Alain C BuretteNeuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Benjamin D PhilpotNeuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Martin A StynerCarolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Heather C HazlettCarolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Cellular and molecular mechanisms governing cortical surface area overgrowth in iPSC-derived neural cells from longitudinally characterized individuals with autismR01HD055741 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph Piven · 2007 to 2026
$52.6M
UNC Neuroscience Center Research Cores: MicroscopyP30NS045892 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZYLKA, MARK J. · 2003 to 2022
$11.5M
Preclinical CoreP50HD103573 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GABRIEL S DICHTER · 2020 to 2026
$9.7M
UNC BIRCWH CAREER DEVELOPMENT PROGRAMK12HD001441 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOGGESS, KIM A · 2000 to 2019
$9.3M
Postdoctoral Research in Neurodevelopmental DisordersT32HD040127 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN D PHILPOT, Mark D Shen · 2001 to 2026
$8.5M
UBE3A gain-of-function and parent-of-origin influence on neurodevelopmental phenotypesR01MH120229 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PHILPOT, BENJAMIN D, ZYLKA, MARK J. · 2019 to 2023
$3.4M
White Matter Pathology in Angelman Syndrome and Its Potential as an Outcome Measure in Clinical TrialsR01HD093771 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAZLETT, HEATHER CODY, PHILPOT, BENJAMIN D · 2018 to 2022
$3.0M
TCF4 in Pitt-Hopkins syndromeR01NS114086 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PHILPOT, BENJAMIN D · 2019 to 2023
$1.7M
Investigating UBE3A as a driver gene in Duplication 15q syndromeR01NS129914 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN D PHILPOT · 2023 to 2026
$1.6M
Super Resolution STED Microscopy at UNCS10OD030300 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GUPTON, STEPHANIE · 2022 to 2022
$600k
White Matter Fiber Tract Pathology in a Genetically-Defined Neurodevelopmental DisorderR56NS097831 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAZLETT, HEATHER CODY, PHILPOT, BENJAMIN D · 2017 to 2017
$544k
NCI NIH HHS P30 CA016086NICHD NIH HHS K12 HD001441NICHD NIH HHS P50 HD103573NICHD NIH HHS R01 HD055741NICHD NIH HHS R01 HD093771NICHD NIH HHS T32 HD040127NIH HHS S10 OD030300NIMH NIH HHS R01 MH120229NINDS NIH HHS P30 NS045892NINDS NIH HHS R01 NS114086NINDS NIH HHS R01 NS129914NINDS NIH HHS R56 NS097831
6 · The paper itself

Abstract

Background: Angelman syndrome (AS), a severe neurodevelopmental disorder resulting from the loss of the maternal Methods: We conducted magnetic resonance imaging (MRI) on children with AS (n=32) and neurotypical controls (n=99) aged 0.5-12 years. In parallel, we examined myelination in postnatal Results: Our data revealed that AS individuals exhibit significant reductions in brain volume by ~1 year of age, with WM reduced by 26% and gray matter by 21% by 6-12 years of age-approximately twice the reductions observed in the adult AS mouse model. In our AS mouse model, we saw a global delay in the onset of myelination, which normalized within days (likely corresponding to months or years in human development). This myelination delay is caused by the loss of UBE3A in neurons rather than UBE3A haploinsufficiency in oligodendrocytes. Interestingly, ultrastructural analyses did not reveal any abnormalities in myelinated or unmyelinated axons. Limitations: It is difficult to extrapolate the timing and duration of the myelination delay observed in AS model mice to individuals with AS. Conclusions: This study reveals WM deficits as a hallmark in children with AS, demonstrating for the first time that these deficits are already apparent at 1 year of age. Parallel studies in a mouse model of AS show that these deficits may be associated with delayed onset of myelination due to the loss of neuronal (but not glial) UBE3A. These findings emphasize the potential of WM as both a therapeutic target for interventions and a valuable biomarker for tracking the progression of AS and the effectiveness of potential treatments.

Identifiers

PMID39149488
PMCPMC11326408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.